Onyvax begins Ph IIb trial of prostate cancer vacc

26 September 2007

London, UK-based biotechnology firm Onyvax says that it has begun a new Phase IIb clinical trial of its immunostimulatory agent, Onyvax-P, which is being developed to treat prostate cancer.

The study, which is being conducted at the US National Cancer Institute in Bathesda, Maryland, is designed to assess the drug in 44 patients with rising prostate-specific antigen levels after receiving localized therapy for primary prostate cancer. Participants will receive three months of androgen deprivation therapy before being randomized to receive 15 administrations of either Onyvax-P, or placebo, over a 12-month period. The program will examine the vaccine's effect on PSA-defined disease progression, PSA doubling time, testosterone recovery and immunological response.

Onyvax said that the NCI study will run in parallel to its ongoing Phase IIb trial of Onyvax-P in non-metastatic hormone-refractory prostate cancer that is being carried out at centers in Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight